Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management
暂无分享,去创建一个
O. Ahmad | Subrata Ghosh | M. Iacucci | A. Akbar | Samuel C. L. Smith | L. Jeffery | U. Shivaji | X. Gui
[1] R. Bell,et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance , 2019, Journal of Immunotherapy for Cancer.
[2] Y. Nakamura. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events , 2019, Front. Med..
[3] N. Sharma,et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[4] Yun-tao Jia,et al. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS , 2019, Clinical Drug Investigation.
[5] M. Iacucci,et al. Endoscopic findings of checkpoint inhibitor–induced ileitis with use of the latest advanced endoscopic optical diagnosis: near-focus narrow-band imaging , 2019, VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy.
[6] G. Coukos,et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. , 2019, The Lancet. Oncology.
[7] A. Charabaty,et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study , 2018, Journal of Immunotherapy for Cancer.
[8] B. Horst,et al. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. , 2018, Melanoma research.
[9] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[10] B. Prabhakar,et al. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. , 2018, Journal of autoimmunity.
[11] B. Helmink,et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis , 2018, Nature Medicine.
[12] R. Amaria,et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis , 2018, Journal of Immunotherapy for Cancer.
[13] G. Raju,et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis , 2018, Journal of Immunotherapy for Cancer.
[14] W. Oh,et al. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab , 2018, Journal of Immunotherapy for Cancer.
[15] A. Tai,et al. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis , 2018, Clinical and Translational Gastroenterology.
[16] N. Chaput,et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review , 2018, Gut.
[17] D. Samuel,et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. , 2018, Journal of hepatology.
[18] D. Karamchandani,et al. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective , 2018, Journal of Clinical Pathology.
[19] Zu-hua Gao,et al. Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment , 2018, Journal of Cancer.
[20] S. Baxi,et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis , 2018, British Medical Journal.
[21] M. Yeh,et al. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury , 2018, Modern Pathology.
[22] E. Rozeman,et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management , 2018, ESMO Open.
[23] N. Agarwal,et al. PD-1 checkpoint inhibition: Toxicities and management. , 2017, Urologic oncology.
[24] K. Shannon,et al. 1220PDPhase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma , 2017 .
[25] M. Wiese,et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers , 2017, British Journal of Cancer.
[26] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[27] Douglas B. Johnson,et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis , 2017, Oncoimmunology.
[28] E. Tartour,et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer , 2017, ESMO Open.
[29] A. Eggermont,et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] G. Lauwers,et al. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies , 2017, The American journal of surgical pathology.
[31] F. Hodi,et al. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients , 2017, Cancer Immunology Research.
[32] T. Janowitz,et al. A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab , 2017, Seminars in oncology.
[33] D. Schadendorf,et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Y. Fujisawa,et al. Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. , 2017, Japanese journal of clinical oncology.
[35] R. Sullivan,et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] M. Brown,et al. Vedolizumab: a novel treatment for ipilimumab-induced colitis , 2016, BMJ Case Reports.
[37] C. Berking,et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. , 2016, Cancer treatment reviews.
[38] D. Planchard,et al. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.
[39] C. Tournigand,et al. Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study. , 2016 .
[40] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[41] T. Jaffe,et al. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis , 2016, Abdominal Radiology.
[42] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[43] J. Kirkwood,et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma , 2015, Journal of Immunotherapy for Cancer.
[44] A. Razak,et al. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] J. Wolchok,et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[47] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[48] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[49] C. Lebbé,et al. Ipilimumab-induced acute severe colitis treated by infliximab. , 2013, Melanoma research.
[50] R. Dummer,et al. Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab , 2013, Cancer.
[51] A. Shinagare,et al. Ipilimumab-associated colitis: CT findings. , 2013, AJR. American journal of roentgenology.
[52] Joseph O. Deasy,et al. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting , 2011 .
[53] R. Kefford,et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[55] S. Targan,et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. , 2010, Cancer immunity.
[56] Loise M. Francisco,et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.
[57] A. Maraveyas,et al. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma , 2009, Clinical Cancer Research.
[58] A. Feldman,et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] A. Lanfranco,et al. CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.